| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11478456 | AZURITY | Oral pharmaceutical composition comprising Zonisamide and process of preparation thereof |
Aug, 2038
(14 years from now) | |
| US11529333 | AZURITY | Oral pharmaceutical composition comprising zonisamide and process of preparation thereof |
Aug, 2038
(14 years from now) | |
Zonisade is owned by Azurity.
Zonisade contains Zonisamide.
Zonisade has a total of 2 drug patents out of which 0 drug patents have expired.
Zonisade was authorised for market use on 15 July, 2022.
Zonisade is available in suspension;oral dosage forms.
Zonisade can be used as a method of treating seizures.
The generics of Zonisade are possible to be released after 18 August, 2038.
Drugs and Companies using ZONISAMIDE ingredient
Market Authorisation Date: 15 July, 2022
Treatment: A method of treating seizures
Dosage: SUSPENSION;ORAL
More Information on Dosage
ZONISADE family patents
